The results are much like other research conducted on semaglutide, which have verified what some have dubbed “copyright rebound.” A review from 2022, found that people who stopped using the drug regained about two-thirds of the burden they'd missing just after one year. promoted beneath the trade name Zepbound, the medication is prescribed for… Read More